# Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data

> **NCT07413250** · — · ACTIVE_NOT_RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria
- PNH

## Interventions

- **DRUG:** Danicopan
- **DRUG:** Soliris/Ultomiris

## Key facts

- **NCT ID:** NCT07413250
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-01-14
- **Primary completion:** 2030-01-15
- **Final completion:** 2030-01-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07413250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07413250, "Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07413250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*